Literature DB >> 11468313

Presynaptic congenital myasthenic syndrome due to quantal release deficiency.

R A Maselli1, D Z Kong, C M Bowe, C M McDonald, W G Ellis, M A Agius, C M Gomez, D P Richman, R L Wollmann.   

Abstract

OBJECTIVE: To provide clinical, electrophysiologic, and ultrastructural findings in three patients with a presynaptic congenital myasthenic syndrome (CMS).
BACKGROUND: Familial infantile myasthenia and paucity of synaptic vesicles are the only two fully characterized CMS. We are describing here three patients with another form of presynaptic CMS characterized by deficiency of the action potential-dependent release without reduction of the spontaneous release of neurotransmitter from the nerve terminal.
METHODS: The authors performed electromyography and anconeus muscle biopsies that included intracellular recordings and electron microscopy of the neuromuscular junction in three patients with presynaptic CMS. They also sequenced part of the P/Q-calcium alpha(1)-subunit gene (CACNA1A) and the acetylcholine receptor subunit (AChR) genes in these patients.
RESULTS: In these patients there were additional neurologic findings including nystagmus and ataxia. In all three patients the end-plate potential quantal content (m) was markedly reduced but neither the amplitudes nor the frequencies of miniature end-plate potentials were diminished. Ultrastructurally, postsynaptic end-plate folds, nerve terminal size, and synaptic vesicle number were normal but double-membrane-bound sacs containing synaptic vesicles were present in the nerve terminal of all three patients. The screening of reported pathogenic mutations in the CACNA1A and a mutational analysis of AChR subunit genes were negative.
CONCLUSION: This form of CMS appears to result only from a deficiency of the quantal release of neurotransmitter that may be due to an abnormal calcium mechanism or impaired endocytosis and recycling of synaptic vesicles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468313     DOI: 10.1212/wnl.57.2.279

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

Review 1.  Congenital myasthenic syndromes: genetic defects of the neuromuscular junction.

Authors:  Kinji Ohno; Andrew G Engel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

Review 2.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

3.  Functional dissection of a eukaryotic dicistronic gene: transgenic stonedB, but not stonedA, restores normal synaptic properties to Drosophila stoned mutants.

Authors:  Patricia S Estes; Taryn C Jackson; Daniel T Stimson; Subhabrata Sanyal; Leonard E Kelly; Mani Ramaswami
Journal:  Genetics       Date:  2003-09       Impact factor: 4.562

Review 4.  The spectrum of congenital myasthenic syndromes.

Authors:  Andrew G Engel; Kinji Ohno; Steven M Sine
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

5.  The primary headaches: genetics, epigenetics and a behavioural genetic model.

Authors:  Pasquale Montagna
Journal:  J Headache Pain       Date:  2008-03-15       Impact factor: 7.277

Review 6.  The ataxic Cacna1a-mutant mouse rolling nagoya: an overview of neuromorphological and electrophysiological findings.

Authors:  Jaap J Plomp; Arn M J M van den Maagdenberg; Simon Kaja
Journal:  Cerebellum       Date:  2009-05-30       Impact factor: 3.847

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.